Oncology · NSCLCTrial Updateclinicalmid-term

BMS's Navlimetostat in NSCLC Trial vs. Placebo and Pembrolizumab

Importance8/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/28/2026, 6:30:57 AM

Assessment confidence: 54% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing trial of Navlimetostat in combination with pembrolizumab and chemotherapy represents a significant opportunity for BMS to enhance its oncology portfolio. A positive outcome could solidify BMS's competitive position in the NSCLC treatment landscape, particularly for patients with MTAP deletion. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 15 ranked evidence items (5 high-relevance).

Strategic Assessment

Success in this trial may enhance BMS's portfolio in oncology and provide a competitive edge in first-line treatment options for NSCLC. The strongest clinical anchor is A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) (ClinicalTrials.gov), sub-indication match (lung cancer); entity match (pembrolizumab).

Competitive Pressure

The most relevant competitive pressure comes from Merck's KEYMAKER-U01 Study Explores Pembrolizumab in NSCLC with Chemotherapy (Humanexa Signals) — sub-indication match (lung cancer); entity match (pembrolizumab). Secondary pressure from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC. This trial could position BMS favorably against competitors in the NSCLC space, particularly if the combination shows superior efficacy.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Sponsor/company relevance (Bristol Myers Squibb); Regulatory pathway relevance (approval). If the trial demonstrates efficacy, it could facilitate expedited regulatory pathways for approval, impacting BMS's timeline for bringing this combination therapy to market.

Key Risks

Elevated medium regulatory exposure for Bristol Myers Squibb could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.
Regulatory risk from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) could weigh on Bristol Myers Squibb through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

Success in this trial could lead to increased market share for BMS in the lucrative NSCLC segment, potentially translating into substantial revenue growth.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Bristol Myers Squibb document relevant to the signal.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any announcements regarding efficacy and safety outcomes.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAmedium relevance
Sponsor/company relevance (Bristol Myers Squibb); Regulatory pathway relevance (approval)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAmedium relevance
Sponsor/company relevance (Bristol Myers Squibb); Regulatory pathway relevance (approval)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAmedium relevance
Sponsor/company relevance (Bristol Myers Squibb); Regulatory pathway relevance (approval)
FDA document
View source
Sunscreen: How to Help Protect Your Skin from the Sun
FDAmedium relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Entity match (pembrolizumab)
FDA document
View source
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
ClinicalTrials.govlow relevance
Entity match (pembrolizumab)
FDA document
View source
A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
ClinicalTrials.govlow relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial
ClinicalTrials.govlow relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

Merck's KEYMAKER-U01 Study Explores Pembrolizumab in NSCLC with Chemotherapy
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Entity match (pembrolizumab)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Pfizer)
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
Bristol Myers Squibbmedium relevance
Entity match (bristol myers squibb)
FDA document
View source
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
Bristol Myers Squibbmedium relevance
Entity match (bristol myers squibb)
FDA document
View source
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schiz
Bristol Myers Squibbmedium relevance
Entity match (bristol myers squibb)
FDA document
View source
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
Bristol Myers Squibbmedium relevance
Entity match (bristol myers squibb)
FDA document
View source
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
Bristol Myers Squibbmedium relevance
Entity match (bristol myers squibb)
FDA document
View source
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
Bristol Myers Squibbmedium relevance
Entity match (bristol myers squibb)
FDA document
View source

Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
PubMedhigh relevance
Sub-indication match (lung cancer); Entity match (pembrolizumab)
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedlow relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedlow relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedlow relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Bristol Myers Squibb
Navlimetostat
Pembrolizumab

Commercial impact

high

Success in this trial could lead to increased market share for BMS in the lucrative NSCLC segment, potentially translating into substantial revenue growth.

Regulatory impact

medium

If the trial demonstrates efficacy, it could facilitate expedited regulatory pathways for approval, impacting BMS's timeline for bringing this combination therapy to market.

What to watch

Monitor trial results and any announcements regarding efficacy and safety outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.